UroGen Pharma Ltd. (URGN)
Last updated: 2026-10-21 16:53:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Summary
UroGen Pharma Ltd. (URGN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $35.75, with a market capitalization of $1.67B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $16.50 to $50.81. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$1.67B | |
$35.25 | |
$69.57 | |
$3.42 | |
$35.01 | |
219.77K | |
893.75K | |
-- | |
$50.81 | |
$16.50 | |
-- | |
-- |
UroGen Pharma Ltd. (URGN) Stock Price Today
UroGen Pharma Ltd. (URGN) is currently trading at $35.75 as of 2026-10-21 16:36:57, up 2.11% ($0.74) from the previous close of $35.01
During today's regular trading session, URGN has traded between $3.42 and $69.57, with a trading volume of 219.77K shares. The current price is near the middle of today's range.
UroGen Pharma Ltd. (URGN) 7-Day Stock Price Change
Over the past seven days, UroGen Pharma Ltd. (URGN) moved from $38.28 to $35.75, representing a decline of 6.61% ($2.53).
The stock traded between $33.40 and $39.09 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 868.80 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
URGN 52-Week Price Position
Position in Range: 56.1%
URGN is currently trading at $35.75, placing it 56.1% of the way from its 52-week low of $16.50 to its 52-week high of $50.81. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is UroGen Pharma Ltd. (URGN)?
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
UroGen Pharma Ltd. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 291 |
| Exchange | NASDAQ |
| Company Website |
How to Buy UroGen Pharma Ltd. (URGN) Stock on MEXC
Eligible investors can buy real shares of UroGen Pharma Ltd. (URGN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is UroGen Pharma Ltd. (URGN) stock price today?
2.Is URGN stock going up or down today?
3.What is URGN pre-market price?
4.What is URGN after-hours price?
5.Is URGN stock trading now?
6.Where does URGN sit relative to its 52-week high and low?
7.What sector is UroGen Pharma Ltd. in?
8.What is UroGen Pharma Ltd.'s market capitalization and where is it listed?
9.How is URGN valued in terms of P/E ratio and EPS?
10.Does UroGen Pharma Ltd. pay a dividend?
Explore More US Stocks
Search Stocks
URGN Stock Calculator
Estimate the value between URGN shares and USD.
URGN Shares to USD
1.00 URGN shares = 35.749 USD
Calculations are estimates based on the latest available price and are for reference only.


